Evidence map›Paper›PMID 33802091›Full record

ReviewInternational journal of molecular sciences2021

Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding, Sepideh Afshar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Enhanced Anti-Inflammatory Effect of the Combination ofMolecules (Basel, Switzerland) · 2022
    Article
  13. Targeting ProteinCells · 2022
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinsha LiuProtein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Joey Paolo TingProtein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Shams Al-AzzamProfessional Scientific Services, Eurofins Lancaster Laboratories, Lancaster, PA 17605, USA.
Yun DingProtein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.
Sepideh AfsharProtein Engineering, Lilly Biotechnology Center, Eli Lilly and Company, San Diego, CA 92121, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 2015, 170 small molecules, 60 antibody-based entities, 12 peptides, and 15 gene- or cell-therapies have been approved by FDA for diverse disease indications. Recent advancement in medicine is facilitated by identification of new targets and mechanisms of actions, advancement in discovery and development platforms, and the emergence of novel technologies. Early disease detection, precision intervention, and personalized treatments have revolutionized patient care in the last decade. In this review, we provide a comprehensive overview of current and emerging therapeutic modalities developed in the recent years. We focus on nine diseases in three major therapeutics areas, diabetes, autoimmune, and neurological disorders. The pathogenesis of each disease at physiological and molecular levels is discussed and recently approved drugs as well as drugs in the clinic are presented.

Indexed as

Autoimmune DiseasesDiabetes MellitusHumansNervous System DiseasesAlzheimer’s Diseaseatopic dermatitisCrohn’s DiseasediabetesinnovationmigraineosteoarthritisParkinson’s Diseaserheumatoid arthritistherapeutic modalities

Identifiers

PMID33802091
PMCPMC8001105

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.